Luis Ayerbe1, Ivo Forgnone2, Quintí Foguet-Boreu3, Esteban González4, Juliet Addo5, Salma Ayis6. 1. Centre of Primary Care and Public Health,Queen Mary University of London,London,UK. 2. Daroca Primary Care Centre,Madrid,Spain. 3. Department of Psychiatry,Vic University Hospital,Vic,Spain. 4. Family Medicine Unit,Department of Medicine,Universidad Autónoma de Madrid,Madrid,Spain. 5. Department of Non-communicable Disease Epidemiology,London School of Hygiene and Tropical Medicine,London,UK. 6. Division of Health and Social Care Research,Kings College London,London,UK.
Abstract
BACKGROUND: The high cardiovascular (CV) morbidity and mortality reported for patients with psychiatric disorders may possibly be due to a poorer management of CV risk factors (CVRFs). However, these healthcare disparities remain poorly understood. In this paper, studies comparing the management of smoking, diabetes, hypertension and dyslipidaemia, in patients with and without depression, anxiety, schizophrenia, bipolar or personality disorder, were reviewed. METHODS: Prospective studies comparing rates of screening, diagnosis, treatment and control of CVRFs were searched in PubMed, Embase, PsychInfo, Scopus and Web of Science (inception to January 2017). The Meta-analysis of Observational Studies in Epidemiology (MOOSE) criteria were used. Studies were assessed for quality. Wherever possible, meta-analyses were conducted to summarize the findings. RESULTS: Twenty studies, out of the 18 333 references initially identified, were included. Most studies were heterogeneous in design. Two areas permitted meta-analyses: the pooled odds ratio for quitting smoking for those with depression was 0.64 (0.49-0.80) p < 0.001; the pooled difference of glycated haemoglobin for patients with type 2 diabetes and depression was 0.18 (0.06-0.31) p = 0.005. Individual studies showed associations between: schizophrenia and lower probability of having smoking habit recorded; schizoid personality disorder and higher probability of remaining non-smokers after quitting; anxiety and poorer control of type I diabetes; depression, anxiety or schizophrenia and lower probability of having a diagnosis of hypertension; schizophrenia or bipolar disorder and lower use of antihypertensive and lipid-lowering drugs. CONCLUSIONS: A proactive clinical management, together with further studies, are needed to reduce the CV morbidity and mortality of patients with psychiatric disorders.
BACKGROUND: The high cardiovascular (CV) morbidity and mortality reported for patients with psychiatric disorders may possibly be due to a poorer management of CV risk factors (CVRFs). However, these healthcare disparities remain poorly understood. In this paper, studies comparing the management of smoking, diabetes, hypertension and dyslipidaemia, in patients with and without depression, anxiety, schizophrenia, bipolar or personality disorder, were reviewed. METHODS: Prospective studies comparing rates of screening, diagnosis, treatment and control of CVRFs were searched in PubMed, Embase, PsychInfo, Scopus and Web of Science (inception to January 2017). The Meta-analysis of Observational Studies in Epidemiology (MOOSE) criteria were used. Studies were assessed for quality. Wherever possible, meta-analyses were conducted to summarize the findings. RESULTS: Twenty studies, out of the 18 333 references initially identified, were included. Most studies were heterogeneous in design. Two areas permitted meta-analyses: the pooled odds ratio for quitting smoking for those with depression was 0.64 (0.49-0.80) p < 0.001; the pooled difference of glycated haemoglobin for patients with type 2 diabetes and depression was 0.18 (0.06-0.31) p = 0.005. Individual studies showed associations between: schizophrenia and lower probability of having smoking habit recorded; schizoid personality disorder and higher probability of remaining non-smokers after quitting; anxiety and poorer control of type I diabetes; depression, anxiety or schizophrenia and lower probability of having a diagnosis of hypertension; schizophrenia or bipolar disorder and lower use of antihypertensive and lipid-lowering drugs. CONCLUSIONS: A proactive clinical management, together with further studies, are needed to reduce the CV morbidity and mortality of patients with psychiatric disorders.
Authors: I H Heiberg; R Nesvåg; L Balteskard; J G Bramness; C M Hultman; Ø Naess; T Reichborn-Kjennerud; E Ystrom; B K Jacobsen; A Høye Journal: Acta Psychiatr Scand Date: 2020-02-29 Impact factor: 6.392
Authors: Ashli Owen-Smith; Christine Stewart; Musu M Sesay; Sheryl M Strasser; Bobbi Jo Yarborough; Brian Ahmedani; Lisa R Miller-Matero; Stephen C Waring; Irina V Haller; Beth E Waitzfelder; Stacy A Sterling; Cynthia I Campbell; Rulin C Hechter; John E Zeber; Laurel A Copeland; Jeffrey F Scherrer; Rebecca Rossom; Greg Simon Journal: BMC Psychiatry Date: 2020-01-31 Impact factor: 3.630
Authors: Elisa Stivanello; Federico Chierzi; Paolo Marzaroli; Sara Zanella; Rossella Miglio; Patrizia Biavati; Vincenza Perlangeli; Domenico Berardi; Angelo Fioritti; Paolo Pandolfi Journal: Int J Environ Res Public Health Date: 2020-12-07 Impact factor: 3.390
Authors: Torleif Ruud; Tordis Sørensen Høifødt; Delia Cimpean Hendrick; Robert E Drake; Anne Høye; Matthew Landers; Kristin S Heiervang; Gary R Bond Journal: Adm Policy Ment Health Date: 2020-11
Authors: Silvana Galderisi; Marc De Hert; Stefano Del Prato; Andrea Fagiolini; Philip Gorwood; Stefan Leucht; Aldo Pietro Maggioni; Armida Mucci; Celso Arango Journal: Eur Psychiatry Date: 2021-01-08 Impact factor: 5.361
Authors: Maarten van Schijndel; Luc Jansen; Jan Busschbach; Jeroen van Waarde; Andre Wierdsma; Henning Tiemeier Journal: BMC Health Serv Res Date: 2022-04-11 Impact factor: 2.655
Authors: Gaia Sampogna; Andrea Fiorillo; Mario Luciano; Valeria Del Vecchio; Luca Steardo; Benedetta Pocai; Marina Barone; Mario Amore; Francesca Pacitti; Liliana Dell'Osso; Giorgio Di Lorenzo; Mario Maj Journal: Front Psychiatry Date: 2018-06-07 Impact factor: 4.157